A Novel Strategy to Mitigate the Hyperinflammatory Response to COVID-19 by Targeting Leukotrienes
SARS-CoV-2 causing coronavirus disease 2019 (COVID-19) has wreaked havoc during the global pandemic of 2020 infecting millions and leaving over a half million dead. As a new virus, not previously in the human population, but with similarities to other coronaviruses causing severe acute respiratory d...
Main Authors: | Colin D. Funk, Ali Ardakani |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2020-08-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2020.01214/full |
Similar Items
-
Hyperinflammatory Immune Response and COVID-19: A Double Edged Sword
by: Li Yin Tan, et al.
Published: (2021-09-01) -
The Immune Response and Immunopathology of COVID-19
by: Esmaeil Mortaz, et al.
Published: (2020-08-01) -
The dual sides of interferon induction in COVID-19 treatment
by: Sadra Nadimi Parashkouhi, et al.
Published: (2021-03-01) -
Phosphodiesterase Inhibitors: Could They Be Beneficial for the Treatment of COVID-19?
by: Mauro Giorgi, et al.
Published: (2020-07-01) -
Parallels in Sepsis and COVID-19 Conditions: Implications for Managing Severe COVID-19
by: Charles Ochieng’ Olwal, et al.
Published: (2021-02-01)